The goal of this clinical trial is to compare the progression free survival of multiple myeloma patients with translocation 11;14 when treated with venetoclax and dexamethasone versus pomalidomide and dexamethasone.
This trial is currently open and accepting patients.
This clinical trial is separated into two different groups, or arms. Participants will be randomly placed into one of the two arms. Both arms of the trial are organized into 28 day cycles. Participants may continue to receive the study treatments unless their myeloma gets worse, they develop bad side effects, or they no longer wish to participate.
Arm 1: Participants randomized into this arm will receive Venetoclax by mouth every day, and dexamethasone by mouth (or intravenously if unable to take by mouth) weekly.
Arm 2: Participants randomized into this arm will receive Pomalidomide by mouth on days 1-21 of each 28 day cycle. Participants will also receive dexamethasone by mouth (or intravenously if unable to take by mouth) weekly.
All participants will have a treatment completion visit and then move into follow up.
There may be an opportunity for participants to be reimbursed for some of their travel expenses for study related visits. Once a participant has established care at one of the study sites, the staff will share the details of potential reimbursement.
The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.
You may be able to join this trial if you:
Enrollment: 244 patients (estimated)View More
Read the latest news and updates on this trial.
If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.
You can explore trial locations from around the US and connect directly with a trial coordinator.Find Nearby Locations
You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.
Still need help? Send us a message